Climans, Seth A.; Mason, Warren P.; Grunfeld, Eva; Chan, Kelvin published the artcile< Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy>, Electric Literature of 112-63-0, the main research area is Glioma; Pneumocystis pneumonia; Temozolomide.
Abstract: Introduction: The treatment of glioma with temozolomide chemoradiotherapy predisposes patients to pneumocystis pneumonia (PCP). Because PCP is a rare outcome, very little is known about specific clin. risk factors for its development in patients with glioma. Methods: We performed a population-based retrospective cohort study of glioma patients undergoing temozolomide chemoradiotherapy 2005 to 2019 in Ontario, Canada. We compared clin. features of patients who did not vs. did develop PCP within one year of chemoradiotherapy. We examined the overall survival of patients by PCP status. Results: There were 5130 patients with glioma treated with temozolomide chemoradiotherapy. Ultimately, 38 patients (0.74%) were diagnosed with PCP within 1 yr of chemoradiotherapy. Most (71%) infections occurred between 0-90 days and 29% occurred between 91-365 days. Median survival was 12.3 mo in patients who did not develop PCP and 8.6 mo in those who did develop PCP (P < 0.001). Trough 90-day lymphocyte counts were lower in the PCP group. When the lymphocytes fell below 0.19 x 109/L (or 0.25 x 109/L among patients without PCP prophylaxis), the risk of PCP was > 3.5%. Conclusions: Pneumocystis pneumonia is rare in glioma patients who receive temozolomide chemoradiotherapy. Infection is associated with shorter survival and the development of lymphopenia. Reserving PCP prophylaxis for patients whose lymphocyte counts drop below 0.25 x 109/L may be a reasonable strategy.
Journal of Neuro-Oncology published new progress about 112-63-0. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Electric Literature of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics